Diaceutics Share Discussion Threads

[chrisdgb] 22/12/2022 12:12

Still hoping for that takeover in 2023.....

[chrisdgb] 25/11/2022 15:44

Some more buying recently, we really need a US takeover.....

[chrisdgb] 05/10/2022 08:15

Good to see some director buying as well....

[chrisdgb] 27/9/2022 07:47

Fantastic looking interim results...........

[hedgehog 100] 27/7/2022 19:17

"DIACEUTICS TO BECOME FOURTH NORTHERN IRISH COMPANY LISTED ON LONDON STOCK EXCHANGE

RONAN LEONARD MARCH 18, 2019

Diaceutics plc, a revenue-generating, and profitable diagnostics data analytics and implementation services company which services the global pharmaceutical industry, today announces that it is seeking a listing on the AIM Market of the London Stock Exchange. This will make Diaceutics the fourth Northern Irish company currently listed on the London Stock Exchange. The company is expected to have a market capitalisation on admission of approximately £53M. ..."




Rockpool Acquisitions (ROC) is a main-listed cash shell, which may be of interest to investors seeking other Northern Ireland investments to DXRX:-

"A listed acquisition vehicle seeking opportunities in Northern Ireland.

Northern Ireland has a good availability of high quality, often internationally-focused, companies. Despite having an estimated 70,000 registered businesses, there are only two other publicly-listed companies predominantly based in Northern Ireland and Rockpool believes that more Northern Ireland businesses could benefit from the ability to tap into deeper pools of capital which access to the public markets provides.

With extensive knowledge and experience of the Northern Ireland market, the directors are seeking to identify and acquire a highly ambitious, Northern Ireland-based company that is focused on significant growth, and provide it with that access, helping that company meet its aspirations and full potential. Target companies will have a valuation of up to £20m."




Rockpool Acquisitions (ROC) 4.75p Market cap. £604K.




ROC has about £950K. cash, and extremely low cashburn.

ROC's large discount at the moment to its cash, despite this extremely low cashburn, looks like a temporary discrepancy - and one that is gradually being addressed by ROC's share price rise, as the market wakes up to the opportunity.

[chrisdgb] 26/7/2022 08:16

Nice looking trading update........

[chrisdgb] 08/7/2022 10:01

Wonder if we will get a trading update soon, caught up in the small cap maelstrom........

[chrisdgb] 23/6/2022 09:47

Someone might be interested in these below £1.......

[chrisdgb] 13/6/2022 10:34

More good contract news......

[chrisdgb] 27/4/2022 11:06

No one else looking..? Rising well here, something brewing?

[chrisdgb] 12/4/2022 14:25

Some interest today..........!

[gizmohican] 24/3/2022 10:21

Pretty poor performance overall imo, bought in at 1.50 cant see this getting back to those levels quickly based on their Net prof before tax. Seems to be a top heavy senoir mgmt co. Another one for the bottom drawer!

[tomps2] 23/3/2022 08:37

Diaceutics (DXRX) full year 2021 results presentation March 2022


Diaceutics Founder & CEO, Peter Keeling, and CFO, Nick Roberts, present full year results for the period ended 31 December 2021. These results show revenue increased 10% to £13.9m. Gross profit increased 13.4% to £10.7m. With a gross margin of 77%. Adjusted EBITDA was £2.3m and profit before tax £0.5m. Net cash £19.7m.


Watch the video here:

Or listen to the podcast here:

[km18] 16/2/2022 18:07

...from last month...

Company overview:Diaceutics plc is involved in the provision of data analytics to assist pharmaceutical companies worldwide. Diaceutics is known for its robust pipeline development and concise diagnostic testing data conducted from a network of laboratories to find partners for collaboration on accurate medicine diagnostics.  This plausible initiative enabled the firm to obtain a competitive advantage and thereby was incorporated into the firm’s financials prospects, where revenue grew 17% and EBITDA leapt to £2.1m from £0.5m. Despite the favourable corporate news, the firm is expected to experience an additional 29% growth in revenue during 2022, illustrated by its CAGR rate....from WealthOracleAM

[chrisdgb] 09/2/2022 15:34

Company is lost on the UK market, should either relist in the US or sell out.......

[chrisdgb] 16/11/2021 12:23

More volume today.....!

[sharesoc] 17/10/2021 10:53

In case you missed it, we have a recording from our webinar with Diaceutics on the 22nd September. See:

[chrisdgb] 30/9/2021 13:35

Decent volume today.......

[sharesoc] 19/9/2021 22:44

Last chance to register for our webinar with Diaceutics PLC on Wednesday. Peter Keeling (CEO & Founder) and Philip White (CFO) will be giving the latest updates:

[tomps2] 17/9/2021 08:15

DXRX interim results presentation September 2021

Diaceutics CEO, Peter Keeling and CFO, Philip White present the half year results for the period ending 30th June 2021.

Watch the video here:

Or listen to the podcast here:

[capitalaccessgroup] 14/9/2021 13:32

Diaceutics Initiation Note

We have today initiated coverage of Diaceutics plc, which has developed the world’s first all-parties marketplace platform (“DXRX”) that allows its clients, pharmaceutical companies, to review and connect with the laboratories and diagnostic companies needed to aid in the development, roll out, & uptake of the diagnostics which enable patient selection for the Pharmas’ Precision Medicines. Key to the investment case is that DXRX is now a heavily invested and scalable platform, with 70%-80% incremental gross margins and a relatively fixed cost base, operating in a high growth industry. It should therefore benefit from material operating leverage as top line growth returns post-pandemic, and we expect margins to grow significantly. You can read it here, or contact us to discuss it with the analyst.

You can find the full research here:
capitalaccessgroup.co.uk/research-portal#/portal/capital-access-group

[chrisdgb] 14/9/2021 09:03

Looking good going forwards, still think this will get picked off........

[sharesoc] 06/9/2021 23:33

We are hosting a webinar with Diaceutics PLC (DXRX) on the 22nd September, which may be of interest to shareholders or potential investors. Peter Keeling (CEO & Founder) and Philip White (CFO) will provide the latest updates: